Roche Signs a License Agreement with Shape to Advance AAV-based RNA Editing Technology for Neuroscience and Rare Disease

August 25, 2021 Auto Bot Biotech, neuroscience, rare disease, Roche 0

Shots:

  • Shape is eligible to receive $3B+ including initial payment, development, regulatory, and sales milestone along with royalties on sales of therapies resulting from the collaboration
  • The collaboration will utilize Shape’s RNA editing platform i.e., RNAfix and AAVid for next-generation tissue-specific AAVs to develop gene therapy for AD, PD & rare diseases
  • Shape to conduct preclinical research to identify & deliver development candidates discovered by RNAfix and AAVid AI-powered platforms. Roche will lead the development & global commercialization of any potential products that emerge from the collaboration

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: PharmaLive

The post Roche Signs a License Agreement with Shape to Advance AAV-based RNA Editing Technology for Neuroscience and Rare Disease first appeared on PharmaShots.